Brincidofovir
- Generic Name
- Brincidofovir
- Brand Names
- Tembexa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H52N3O7P
- CAS Number
- 444805-28-1
- Unique Ingredient Identifier
- 6794O900AX
- Background
Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy. Due to its formulation as a pro-dr...
- Indication
Brincidofovir is indicated for the treatment of human smallpox disease in adult and pediatric patients.
- Associated Conditions
- Variola Major (Smallpox)
- Associated Therapies
- -
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 452
- Registration Number
- NCT01769170
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸The Universit of Iowa, Iowa City, Iowa, United States
🇺🇸University of California, San Diego-Moores Cancer Center, La Jolla, California, United States
Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 52
- Registration Number
- NCT01241344
- Locations
- 🇺🇸
St. Louis Children's Hosptial, Saint Louis, Missouri, United States
🇺🇸Harvard-Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 210
- Registration Number
- NCT01143181
- Locations
- 🇺🇸
Children's Hospital of LA, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 239
- Registration Number
- NCT00942305
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
CMX001 in Post-transplant Patients With BK Virus Viruria
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 29
- Registration Number
- NCT00793598
- Locations
- 🇺🇸
Tulane Center for Abdominal Transplant, New Orleans, Louisiana, United States
🇺🇸Mt. Sinai Medical Center, New York, New York, United States
🇺🇸UNC Kidney Center, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.